PRTG (Portage Biotech Inc.) Net earnings per share growth this year

Portage Biotech Inc. (PRTG) develops immuno-oncology treatments, attracting scientists with the opportunity to make discoveries within a boutique scientific environment. The company is actively developing innovative methods for combating tumors. The 12-month earnings per share growth rate demonstrates financial dynamics where 0.00 serves as the current metric level. Business success depends on regulators and clinical efficacy, while macroeconomics only influences access to capital.

Earnings per share growth in current year: Portage Biotech Inc (PRTG) for 07/04/2022 - 09/04/2025

Financial and market metric breakdowns for Portage Biotech Inc. (PRTG)

- stock quotes and analyst forecast:

Share Price Portage Biotech Inc|PRTG - Analyst Consensus Forecast

- business market valuation indicators:

Market Valuation Portage Biotech Corp|PRTG - Total Company Value

- company book value details:

Net Asset Value per Share Portage Biotech|PRTG - Company Book Value|Market Value to Book Value Ratio portagebiotech.com|PRTG - Aggregate Company Assets

- debt and liquidity details:

- company profitability and valuation multiples indicators:

PRTG - Net Profit|Expected Net Income Portage Biotech Inc.|PRTG - P/E Multiple|Projected Price to Earnings Ratio Portage Biotech Corp|PRTG - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Portage Biotech Corp|PRTG - Operating profit EBITDA|Net earnings per share (EPS TTM) Portage Biotech|PRTG - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months portagebiotech.com|PRTG - Net earnings per share growth this year|Expected net earnings per share growth next year Portage Biotech Inc.

- revenue and sales proceeds data:

PRTG - Company Revenue|Company Expected Revenue Portage Biotech Inc|PRTG - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Portage Biotech Corp

Summary company analysis:PRTG Portage Biotech Inc

Signature product of Portage Biotech Inc.

This indicator measures the annual growth of earnings per share, revealing the actual efficiency of capital generation relative to previous periods. The formula's high sensitivity to operational data allows for the immediate capture of fundamental changes between quarterly reports. By analyzing the year-over-year shift in EPS metrics, an investor can assess how closely the development of innovative cancer immunotherapy at Portage Biotech Inc. (PRTG) is approaching the stage of commercial monetization.

Key competitors